Omidenepag is primarily used in the treatment of glaucoma and ocular hypertension. It functions as a selective prostaglandin EP2 receptor agonist, which helps to reduce intraocular pressure by increasing the outflow of aqueous humor from the eye. This mechanism makes it effective in managing conditions that could otherwise lead to optic nerve damage and vision loss. Its application is particularly beneficial for patients who may not respond adequately to other intraocular pressure-lowering medications. Omidenepag is typically administered as an ophthalmic solution, ensuring direct and targeted action within the eye. Its use is often monitored to assess efficacy and manage any potential side effects.